Primarily because you never comment on much positives about the company.
Had it not been for the FDA mess with Lovenox and subsequent mess by the courts re MNTA patent/FDA disclosure of proprietary info - MNTA would have enjoyed additional revenue for a while.
Copaxone approval - 99.9% in my opinion, imminent launch.
This should carry the company until additional revenue is generated with Baxter and advancement of pipeline.